###begin article-title 0
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="author-notes" rid="fn2">2</xref>
PECAM-1 engagement counteracts ICAM-1-induced signaling in brain vascular endothelial cells2
###end article-title 0
###begin p 1
These authors contributed equally to this work.
###end p 1
###begin p 2
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 2
###begin p 3
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 3
###begin p 4
Interactions between leukocytes and vascular endothelial cells are mediated by a complex set of membrane adhesion molecules which transduce bi-directional signals in both cell types. Endothelium of the cerebral blood vessels, which constitute the blood-brain barrier, strictly controls adhesion and trafficking of leukocytes into the brain. Investigating signaling pathways triggered by the engagement of adhesion molecules expressed on brain endothelial cells, we previously documented the role of ICAM-1 in activation of the tyrosine phosphorylation of several actin-binding proteins and subsequent rearrangements of the actin cytoskeleton. In the present study, we show that, whereas PECAM-1 is known to control positively the trans-endothelial migration of leukocytes via homophilic interactions between leukocytes and endothelial cells, PECAM-1 engagement on brain endothelial surface unexpectedly counteracts the ICAM-1-induced tyrosine phosphorylation of cortactin and rearrangements of the actin cytoskeleton. We present evidence that the PECAM-1-associated tyrosine phosphatase SHP-2 is required for ICAM-1 signaling, suggesting that its activity might crucially contribute to the regulation of ICAM-1 signaling by PECAM-1. Our findings reveal a novel activity for PECAM-1 which, by counteracting ICAM-1-induced activation, could directly contribute to limit activation and maintain integrity of brain vascular endothelium.
###end p 4
###begin p 5
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 247 267 247 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">Schenkel <italic>et al.</italic> 2004</xref>
###xml 331 343 331 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">Butcher 1991</xref>
###xml 769 775 769 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 762 780 762 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">Carson <italic>et al.</italic> 2006</xref>
###xml 782 797 782 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">Engelhardt 2006</xref>
Leukocyte extravasation into tissues involves a complex set of adhesion molecules at the surface of leukocytes and vascular endothelial cells. Tethering or rolling of leukocytes is followed by their firm adhesion to endothelium, their locomotion (Schenkel et al. 2004) at the endothelial surface, which itself precedes diapedesis (Butcher 1991). In the central nervous system, brain endothelial cells are joined by continuous tight junctions, constituting the blood-brain barrier (BBB), which strictly limits leukocyte infiltration, as well as drug access to the cerebral compartment. Nevertheless, in pathological situations, such as multiple sclerosis, viral or bacterial infections, numerous activated lymphocytes, monocytes or neutrophils can cross the BBB (Carson et al. 2006; Engelhardt 2006).
###end p 5
###begin p 6
###xml 394 400 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 387 405 387 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">Muller <italic>et al.</italic> 1993</xref>
###xml 663 669 663 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 654 674 654 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">Graesser <italic>et al.</italic> 2002</xref>
On the endothelial apical surface, ICAM-1 is a key player in firm adhesion and locomotion steps. In addition, PECAM-1, which is expressed in endothelial cells, monocytes, neutrophils and specific T lymphocyte subsets, is directly involved in diapedesis via homophilic interactions between migrating leukocytes, particularly monocytes/neutrophils and endothelial intercellular junctions (Muller et al. 1993). Paradoxically, however, gene deficiency for PECAM-1 was recently found to increase the number of activated leukocytes crossing the BBB, suggesting that PECAM-1 might play a more complex role in leukocyte extravasation than previously recognized (Graesser et al. 2002).
###end p 6
###begin p 7
###xml 410 412 410 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 648 654 648 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 631 659 631 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Durieu-Trautmann <italic>et al.</italic> 1994</xref>
###xml 671 677 671 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 661 682 661 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Greenwood <italic>et al.</italic> 2002</xref>
###xml 684 708 684 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Carman and Springer 2004</xref>
###xml 715 721 715 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 710 726 710 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">Shaw <italic>et al.</italic> 2004</xref>
###xml 733 739 733 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 728 744 728 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">Yang <italic>et al.</italic> 2005</xref>
###xml 753 759 753 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 746 764 746 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">Millan <italic>et al.</italic> 2006</xref>
###xml 1072 1078 1072 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1065 1083 1065 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">Newman <italic>et al.</italic> 2001</xref>
###xml 1085 1107 1085 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">Newman and Newman 2003</xref>
These adhesion molecules have been well documented as signal transducers in leukocytes and endothelial cells, in as much as leukocyte adhesion to endothelial cells as well as antibody cross-linking were shown to activate multiple signaling pathways in both cell types. Using brain endothelial cell lines, we previously provided evidence that ICAM-1 antibody cross-linking led to an increase in intracellular Ca2+ concentration, protein kinase C activation, phosphorylation of cortactin and other actin-binding proteins by the Src tyrosine kinase, activation of RhoA GTPase, and subsequent rearrangements of the actin cytoskeleton (Durieu-Trautmann et al. 1994; Greenwood et al. 2002; Carman and Springer 2004; Shaw et al. 2004; Yang et al. 2005; Millan et al. 2006). Besides, PECAM-1 has been abundantly documented as a signaling receptor which can transduce either inhibitory or stimulatory signals with cell-specificity, such as inhibition of the antigen receptor signaling in T lymphocytes or stimulation of the intracellular calcium level in endothelial cells (Newman et al. 2001; Newman and Newman 2003).
###end p 7
###begin p 8
###xml 815 821 815 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 804 826 804 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">Schweitzer <italic>et al.</italic> 1997</xref>
###xml 837 843 837 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 828 848 828 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">Hoffmann <italic>et al.</italic> 2001</xref>
###xml 699 702 <span type="species:ncbi:10116">rat</span>
However, no evidence to our knowledge has emerged on how the two activated signaling pathways coupled to ICAM-1 and PECAM-1 are integrated by endothelial cells and to what extent they might contribute in a sequential and coordinated manner to the endothelial response to leukocyte adhesion. In the present study, we addressed the question of a putative cross-talk between these two signaling pathways by sequential antibody cross-linking of ICAM-1 and PECAM-1 at the surface of endothelial cells: this experimental approach has been shown by us and others to mimic leukocyte interaction with endothelial cells and to allow the biochemical analysis of endothelial response to leukocyte adhesion. The rat brain endothelial cell line RBE4 was used here as a robust model of brain microvascular endothelium (Schweitzer et al. 1997; Hoffmann et al. 2001); We report in the present study that PECAM-1 engagement unexpectedly down-regulated ICAM-1-induced tyrosine phosphorylation of cortactin and rearrangements of the actin cytoskeleton. The functional relevance of this finding is discussed in terms of regulation of BBB integrity in inflammatory situations.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
Abs and reagents
###end title 10
###begin p 11
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 13 16 <span type="species:ncbi:10116">rat</span>
###xml 320 323 <span type="species:ncbi:10116">rat</span>
###xml 429 435 <span type="species:ncbi:9986">Rabbit</span>
###xml 441 446 <span type="species:ncbi:10090">mouse</span>
###xml 448 451 <span type="species:ncbi:10090">RAM</span>
Mouse mAb to rat ICAM-1 (clone 1A29), Major Histocompatibility Complex (MHC) class II (OX6) and Transferrin receptor (OX26) were purchased from Serotec (Wiesbaden, Germany). Anti-PECAM-1 mAb 4E8 and anti-ICAM-1 mAb 3H8 were kindly provided by Dr Hickey (Darmouth Medical School, Hanover, NH, USA). M20 polyclonal Abs to rat PECAM-1, anti-SHP2 and anti-RhoA mAb were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-mouse (RAM) Abs were from DaKo France (Trappes, France). Anti-phosphotyrosine and -cortactin mAbs were purchased from Upstate Biotechnology/Millipore (Billerica, MA, USA). Calpeptin was purchased from Calbiochem (La Jolla, CA, USA). Tetramethylrhodamine isothiocyanate-conjugated phalloidin was purchased from Sigma-Aldrich (St Louis, MO, USA).
###end p 11
###begin title 12
Endothelial cell lines
###end title 12
###begin p 13
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 107 123 107 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">Roux <italic>et al.</italic> 1994</xref>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 125 155 125 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Etienne-Manneville <italic>et al.</italic> 2000</xref>
###xml 224 230 224 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 205 235 205 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Etienne-Manneville <italic>et al.</italic> 2000</xref>
###xml 316 322 316 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 305 327 305 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">Schweitzer <italic>et al.</italic> 1997</xref>
###xml 478 484 478 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 469 489 469 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">Hoffmann <italic>et al.</italic> 2001</xref>
###xml 4 7 <span type="species:ncbi:10116">rat</span>
###xml 242 247 <span type="species:ncbi:9606">human</span>
The rat brain microvascular endothelial (RBE4) cell line was produced by us and extensively characterized (Roux et al. 1994; Etienne-Manneville et al. 2000). RBE4 cells were grown as previously described (Etienne-Manneville et al. 2000). The human bone marrow microvascular endothelial (HBMEC) cell line (Schweitzer et al. 1997) was kindly provided by Dr B. Weksler (Weill Medical College of Cornell University, New York). HBMECs were cultured as previously described (Hoffmann et al. 2001). Both cell lines maintain in culture a fully differentiated endothelial phenotype.
###end p 13
###begin p 14
###xml 224 230 224 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 217 235 217 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">Rivard <italic>et al.</italic> 1995</xref>
###xml 362 363 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 603 607 <span type="species:ncbi:9913">calf</span>
Generation of HBMEC stable transfectants: HBMECs were transfected with either the pcDNA3.1-SHP-2 (human wild type) or pcDNA3.1-DnSHP-2 (Dominant negative) or "empty" plasmid ("mock") kindly provided by Dr C. Nahmias (Rivard et al. 1995) using the nucleofector system developed by Amaxa Inc (Gaithersburg, MD, USA). Briefly, for optimal transfection of HBMECs, 106 cells were suspended in 100 muL of solution V provided by Amaxa in the presence of 1.5 mug DNA, and subjected to electroporation using the program U15 of the nucleofector system. Cells were replated in complete medium containing 10% fetal calf serum. The day after 400 mug/mL active G418 (Invitrogen, Cergy Pontoise, France) were added to the cells. In order to obtain clonal transfectants, selected neomycin plates were split to obtain isolated colonies. The clones and pools (containing multiple clones) were screened for SHP-2 expression by western blotting with specific anti-SHP2 antibodies. One pool and several clones expressing the dominant negative form of SHP-2 (HBMEC/Dn-SHP-2) or wild type SHP-2 (HBMEC/WT-SHP-2) and one pool transfected with empty plasmid (HBMEC/mock) were chosen for further studies. Stable transfectants were maintained in G418 and passaged before attaining confluence.
###end p 14
###begin title 15
Ab cross-linking of ICAM-1 and PECAM-1
###end title 15
###begin p 16
###xml 373 379 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 365 384 361 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Etienne <italic>et al.</italic> 1998</xref>
###xml 405 411 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 386 416 382 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Etienne-Manneville <italic>et al.</italic> 2000</xref>
###xml 428 434 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 418 439 414 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Greenwood <italic>et al.</italic> 2002</xref>
###xml 550 556 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 542 561 538 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Etienne <italic>et al.</italic> 1999</xref>
Confluent endothelial cells were pre-incubated with serum- and growth factor-free culture medium containing 100 U/mL IFN-gamma for 48 h, before Ab cross-linking of ICAM-1 and/or PECAM-1. This treatment has been shown to increase significantly the surface expression of ICAM-1 in RBE4 cells and was thus included in the ICAM-1 cross-linking procedure, as described (Etienne et al. 1998; Etienne-Manneville et al. 2000; Greenwood et al. 2002). In addition, it was also previously reported to induce MHC II surface expression in the same cells (Etienne et al. 1999).
###end p 16
###begin p 17
###xml 84 85 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 115 122 109 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 383 389 <span type="species:ncbi:9986">rabbit</span>
###xml 395 400 <span type="species:ncbi:10090">mouse</span>
###xml 402 405 <span type="species:ncbi:10090">RAM</span>
###xml 717 720 <span type="species:ncbi:10090">RAM</span>
Ab cross-linking was performed in four sequential steps at 37degreesC, under a 5% CO2 atmosphere, as summarized in Table 1: (i) cells were incubated for 15-min with serum-free medium alone (-) or with anti-ICAM-1 antibody (5 or 10 mug/mL); (ii) after two washes with serum-free medium alone to remove unbound antibodies, cells were incubated for 10-min with medium alone (-) or with rabbit anti-mouse (RAM 10 mug/mL) antibodies; (iii) cells were next washed twice and incubated for 15-min with serum-free medium alone (-), with anti-PECAM-1 antibody (10 mug/mL) or with an isotype-matched anti-MHC II antibody (10 mug/mL); (iv) finally, after two washes, cells were incubated for 10-min with medium alone (-) or with RAM antibodies (10 mug/mL).
###end p 17
###begin p 18
Experimental procedure for sequential cross-linking of ICAM-1 and/or PECAM-1 at the surface of cultured endothelial cells
###end p 18
###begin p 19
###xml 272 278 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 255 283 251 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Durieu-Trautmann <italic>et al.</italic> 1994</xref>
###xml 293 299 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 285 304 281 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Etienne <italic>et al.</italic> 1999</xref>
###xml 316 322 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 306 327 302 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Greenwood <italic>et al.</italic> 2002</xref>
The anti-MHC II antibody used here as an isotype-matched control antibody was previously shown not only to bind to IFN-gamma-activated RBE4 cells, but also to trigger signaling pathways in RBE4 cells distinct from those activated by ICAM-1 cross-linking (Durieu-Trautmann et al. 1994; Etienne et al. 1999; Greenwood et al. 2002).
###end p 19
###begin p 20
In order to inhibit SHP-2 phosphatase, endothelial cells (RBE-4 or HBMECs) were treated with 150 mug/mL of calpeptin (Calbiochem, La Jolla, CA, USA) for 30 min prior to ICAM-1 cross-linking.
###end p 20
###begin title 21
Immunofluorescence analysis
###end title 21
###begin p 22
###xml 278 284 278 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 259 289 259 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Etienne-Manneville <italic>et al.</italic> 2000</xref>
Cells grown to confluence on Permanox coverslips (Costar, Corning, NY, USA), were starved in serum-and growth factor-free medium for 24 h, and then treated as described above for antibody cross-linking. F-actin staining was performed as previously described (Etienne-Manneville et al. 2000) and fluorescence images were collected using a scanning confocal microscope (MCR. 1000; Bio-Rad, Hercules, CA, USA). At least three independent experiments were performed in triplicates.
###end p 22
###begin title 23
Immunoprecipitations and western blotting analysis
###end title 23
###begin p 24
Following treatments, cells were washed with ice-cold phosphate-buffered saline and lysed for 30 min at 4degreesC for - cortactin and ICAM-1 experiments: in Nonidet P-40 buffer containing 10 mmol/L Tris-HCl, pH 7.5, 140 mmol/L NaCl, 1% NP-40, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L orthovanadate, 50 units/mL aprotinin, 1 mmol/L EDTA, 2 mug/mL pepstatin, 2 mug/mL leupeptin.
###end p 24
###begin p 25
###xml 157 158 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 173 174 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
PECAM-1 experiments: cells were lysed in Nonidet P-40 buffer containing 50 mmol/L Tris-HCl, pH 7.5, 250 mmol/L NaCl, 0.5% NP-40, 5 mmol/L EDTA, 1 mmol/L CaCl2, 1 mmol/L MgCl2, supplemented with the same protease inhibitors used in cortactin lysis buffer.
###end p 25
###begin p 26
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 329 330 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 419 425 407 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 400 430 388 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Etienne-Manneville <italic>et al.</italic> 2000</xref>
###xml 246 251 <span type="species:ncbi:10090">mouse</span>
Nuclei were discarded following centrifugation at 13 000 g for 10 min at 4degreesC. Cleared lysates were incubated for 3 h at 4degreesC with specific Abs, then for 2 h with agarose beads which were pre-incubated for 2 h with an excess of control mouse immunoglobulins. Immunoprecipitates were collected by centrifugation at 1200 g and processed for western blotting analysis as previously described (Etienne-Manneville et al. 2000). At least three independent experiments were performed in triplicates.
###end p 26
###begin title 27
RhoA activity assay
###end title 27
###begin p 28
###xml 116 117 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 359 365 351 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 354 370 346 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">Reid <italic>et al.</italic> 1996</xref>
###xml 372 395 364 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">Sander and Collard 1999</xref>
###xml 544 550 536 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 536 555 528 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Etienne <italic>et al.</italic> 1998</xref>
Cells were lysed in 50 mmol/L Tris pH 7.5, 150 mmol/L NaCl, 10% glycerol, 1% NP-40, 0.1% Triton X-100, 5 mmol/L MgCl2, 0.1 mmol/L phenylmethylsulfonyl fluoride, 10 mug/mL leupeptine, 10 mug/mL aprotinin. Cleared lysates were incubated with bacterially produced GST-RBD (Rhotekin) bound to glutathione-agarose beads for 45 min at 4degreesC, as described (Reid et al. 1996; Sander and Collard 1999). The beads were washed three times with lysis buffer, and then bound proteins were analyzed by SDS-PAGE and western blotting as described (Etienne et al. 1998). At least three independent experiments were performed in triplicates.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
PECAM-1 cross-linking inhibits ICAM-1-induced actin cytoskeleton rearrangements
###end title 30
###begin p 31
In order to assess the existence of a putative cross-talk between the signaling pathways coupled to ICAM-1 and PECAM-1 in brain endothelial cells, we developed a procedure of sequential antibody cross-linking of ICAM-1 and PECAM-1 (see Materials and methods) to mimic the supposed sequence of events supporting leukocyte extravasation.
###end p 31
###begin p 32
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 183 202 183 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Etienne <italic>et al.</italic> 1998</xref>
###xml 212 218 212 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 204 223 204 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Adamson <italic>et al.</italic> 1999</xref>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 225 255 225 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Etienne-Manneville <italic>et al.</italic> 2000</xref>
###xml 262 268 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 257 273 257 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">Yang <italic>et al.</italic> 2006</xref>
###xml 414 421 414 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1a</xref>
###xml 518 525 518 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1b</xref>
###xml 686 693 686 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1c</xref>
###xml 823 830 823 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1d</xref>
###xml 960 967 960 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1e</xref>
###xml 73 76 <span type="species:ncbi:10116">rat</span>
###xml 383 389 <span type="species:ncbi:9986">Rabbit</span>
###xml 395 400 <span type="species:ncbi:10090">Mouse</span>
###xml 1168 1173 <span type="species:ncbi:9606">human</span>
###xml 1384 1389 <span type="species:ncbi:9606">human</span>
We previously documented that ICAM-1 cross-linking at the surface of the rat brain endothelial RBE4 cells lead to actin cytoskeleton rearrangements through activation of RhoA GTPase (Etienne et al. 1998; Adamson et al. 1999; Etienne-Manneville et al. 2000; Yang et al. 2006). Here, we confirmed that, whereas polymerized actin was mainly cortical in basal condition (incubation with Rabbit anti-Mouse antibodies) (Fig. 1a), ICAM-1 cross-linking induced the formation of numerous actin stress fibers across RBE4 cells (Fig. 1b); this response was maintained over the entire incubation period (50 min). By contrast, no stress fiber formation was observed following PECAM-1 cross-linking (Fig. 1c). Unexpectedly, we did not observe any stress fiber formation following sequential antibody cross-linking of ICAM-1 and PECAM-1 (Fig. 1d). As control, cross-linking of ICAM-1 followed by incubation with buffer alone or with the isotype-matched anti-MHC-II antibody (Fig. 1e) or anti-transferrin antibody (not shown) or again with the same anti-ICAM-1 antibody (not shown) did not affect the ICAM-1-induced formation of stress fibers. Similar results were observed using the human microvascular endothelial cell line HBMEC of peripheral origin (not shown). These results indicate that PECAM-1 engagement drastically blocked the ICAM-1-induced cortical actin polymerization in RBE4 cells and human endothelial cells.
###end p 32
###begin p 33
PECAM-1 cross-linking reverses ICAM-1-induced actin cytoskeleton rearrangements. Sequential cross-linking of ICAM-1 and/or PECAM-1 was performed on IFN-gamma-treated RBE4 cells as described in Material and methods. Panels (a-e) Cells were fixed and actin was stained by using 0.1 mug/mL of tetramethylrhodamine isothiocyanate-labeled phalloidin. Panel (a) basal condition. Panel (b) ICAM-1 cross-linking. Panel (c) PECAM-1 cross-linking. Panel (d) Sequential ICAM-1 and then PECAM-1 cross-linking. Panel (e) As a control, sequential ICAM-1 and then MHC-II cross-linking. Panel (f) GST-Rhotekin pull-down. Proteins were eluted with SDS-sample buffer, and resolved on a 12% SDS-PAGE followed by immunoblotting with anti-RhoA specific or anti-GST antibody. Lane a: basal condition; lane b: ICAM-1 cross-linking; lane c: PECAM-1 cross-linking; lane d: sequential ICAM-1 and then PECAM-1 cross-linking; lane e: sequential ICAM-1 and then MHC-II cross-linking.
###end p 33
###begin p 34
###xml 483 489 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 478 494 478 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">Reid <italic>et al.</italic> 1996</xref>
###xml 496 519 496 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">Sander and Collard 1999</xref>
###xml 827 834 827 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1f</xref>
###xml 875 882 875 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1f</xref>
###xml 1024 1030 1024 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">per se</italic>
###xml 1054 1061 1054 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1f</xref>
###xml 1129 1136 1129 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1f</xref>
###xml 1247 1254 1247 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1f</xref>
Because actin stress fiber formation is known as a RhoGTPase-mediated process, we evaluated this activity in RBE4 cell extracts in the same conditions of ICAM-1 and/or PECAM-1 antibody cross-linking. For that purpose, we used a validated pull-down assay based on the specific interaction between the activated GTP-bound RhoA (compared to the non-activated GDP-bound RhoA) and the RhoA-binding domain (RBD) of the RhoA effector Rhotekin fused to glutathione-S-transferase (GST) (Reid et al. 1996; Sander and Collard 1999). Following ICAM-1 cross-linking or control treatment, cell extracts containing equal amounts of RhoA protein (as confirmed by western blotting: not shown) were incubated with the the Rhotekin-GST fusion protein: a large amount of retained (i.e. activated) RhoA was detected following ICAM-1 cross-linking (Fig. 1f, lane b), compared to basal conditions (Fig. 1f, lane a), confirming our previous finding that ICAM-1 cross-linking induces a strong activation of RhoA in RBE4 cells. PECAM-1 cross-linking per se did not activate RhoA (Fig. 1f, lane c), but completely inhibited ICAM-1-induced RhoA activation (Fig. 1f, lane d). As a control, the irrelevant isotype-matched anti-MHC-II antibody had no effect on ICAM-1 response (Fig. 1f, lane e). These results provide further evidence that PECAM-1 cross-linking affects the ICAM-1-induced cortical actin polymerization by interfering with RhoA activation.
###end p 34
###begin title 35
PECAM-1 cross-linking inhibits ICAM-1-induced cortactin phosphorylation
###end title 35
###begin p 36
###xml 324 330 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 307 335 307 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Durieu-Trautmann <italic>et al.</italic> 1994</xref>
###xml 345 351 345 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 337 356 337 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Etienne <italic>et al.</italic> 1998</xref>
###xml 377 383 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 358 388 358 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Etienne-Manneville <italic>et al.</italic> 2000</xref>
Together with actin polymerization, we previously documented that ICAM-1 cross-linking strongly stimulated the tyrosine kinase Src activity and tyrosine phosphorylation of several actin-binding proteins, including cortactin. This response was maintained over extended periods of time (for at least 60 min) (Durieu-Trautmann et al. 1994; Etienne et al. 1998; Etienne-Manneville et al. 2000). In order to assess whether PECAM-1 engagement might affect ICAM-1-induced cortactin phosphorylation, we performed the same sequential antibody cross-linking of ICAM-1 and PECAM-1 at the surface of RBE4 cells.
###end p 36
###begin p 37
###xml 12 18 12 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2</xref>
###xml 115 122 115 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2a</xref>
###xml 190 197 190 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2a</xref>
###xml 267 274 267 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2a</xref>
###xml 405 412 401 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2a</xref>
###xml 608 615 604 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2b</xref>
As shown in Fig. 2, while ICAM-1 cross-linking strongly enhanced cortactin tyrosine phosphorylation in RBE4 cells (Fig. 2a, lanes b and c), PECAM-1 cross-linking, which had no effect alone (Fig. 2a, lane d), markedly reduced ICAM-1-induced cortactin phosphorylation (Fig. 2a, lane e). As a control, cross-linking of the IFN-gamma -induced MHC class II proteins by an isotype-matched anti-MHC-II antibody (Fig. 2a, lane f) or of transferrin receptors (not shown) did not affect ICAM-1-induced cortactin phosphorylation. Moreover, similar results were observed using the non-brain endothelial cell line HBMEC (Fig. 2b). Partial inhibition of ICAM-1-induced cortactin phosphorylation was already observed after only 5 min of PECAM-1 cross-linking (not shown).
###end p 37
###begin p 38
PECAM-1 cross-linking reverses ICAM-1-induced cortactin phosphorylation. Sequential cross-linking of ICAM-1 and/or PECAM-1 was performed on IFN-gamma-treated RBE4 cells or HBMECs as described in Material and methods. Immunoprecipitated proteins were eluted with SDS-sample buffer, and resolved on 7.5% SDS-PAGE followed by immunoblotting with anti-phosphotyrosine (4 G10) or anti-cortactin antibodies. Panel (a) Cortactin immunoprecipitation using RBE4 cells. Panel (b) Cortactin immunoprecipitation using HBMECs. Lane a: basal condition; lanes b and c: ICAM-1 cross-linking (b, 5 mug/mL and c, 10 mug/mL of ICAM-1 antibodies); lane d: PECAM-1 cross-linking (10 mug/mL); lane e: sequential ICAM-1 and then PECAM-1 (10 mug/mL each) cross-linking; lane f: sequential ICAM-1 and then MHC class II cross-linking (10 mug/mL each). Panel (c) PECAM-1 cross-linking prevents ICAM-1-induced cortactin phosphorylation in RBE4 cells. Lane a: basal condition; lane b: ICAM-1 cross-linking (10 mug/mL of ICAM-1 antibodies); lane e (duplicates): ICAM-1 cross-linking followed by PECAM-1 cross-linking (I + P) (10 mug/mL antibodies); lane f (duplicates): PECAM-1 cross-linking followed by ICAM-1 cross-linking (P + I) (10 mug/mL antibodies).
###end p 38
###begin p 39
###xml 225 234 225 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2c</xref>
###xml 339 346 339 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2c</xref>
###xml 433 440 433 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2c</xref>
Furthermore, in order to assess whether PECAM-1 cross-linking could not only reduce ICAM-1-mediated response in RBE4 cells, but also prevent it, we then performed sequential cross-linking of PECAM-1 and ICAM-1 in this order. Figure 2c reveals that inhibition of ICAM-1-induced cortactin phosphorylation was even more drastic in this case (Fig. 2c, lanes P + I) than when PECAM-1 cross-linking followed ICAM-1 cross-linking as above (Fig. 2c, lanes I + P).
###end p 39
###begin p 40
Altogether, these findings support the conclusion that PECAM-1 engagement on the surface of brain (and non-brain) endothelial cells drastically inhibits multiple ICAM-1 signaling pathways, including cortactin phosphorylation and actin rearrangements.
###end p 40
###begin title 41
The tyrosine phosphatase SHP-2 is at the crossroad between ICAM-1 and PECAM-1-coupled signaling pathways
###end title 41
###begin p 42
###xml 428 435 428 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Fig. 3a</xref>
The tyrosine phosphatase SHP-2, is known to bind to activated PECAM-1. To gain insight into the molecular mechanisms mediating the observed inhibition of ICAM-1 signaling by PECAM-1 cross-linking, we then tested the hypothesis that SHP-2 might be involved in this process. Following PECAM-1 antibody cross-linking, we consistently observed a robust tyrosine phosphorylation of PECAM-1 and its interaction with SHP-2 as shown in Fig. 3a (lane b); the other known PECAM-1-interacting phosphatases SHP-1 and SHIP were not detected in the endothelial cells used in this study (data not shown).
###end p 42
###begin p 43
SHP-2 is recruited by cross-linked ICAM-1 and PECAM-1. Panel (a) Cross-linking of ICAM-1 or PECAM-1 was performed on IFN-gamma-treated RBE4 cells as described in Material and methods. Immunoprecipitated proteins were eluted with SDS-sample buffer, and resolved on 7.5% SDS-PAGE followed by immunoblotting with anti-phosphotyrosine (4 G10) or anti-ICAM1 or PECAM-1 antibodies or with anti-SHP-2 antibody. Lane a: basal condition; lane b: PECAM-1 cross-linking; lane c: basal condition; lane d: ICAM-1 cross-linking. Panel (b) Sequential cross-linking of ICAM-1 and/or PECAM-1 was performed on IFN-gamma-treated mock-transfected HBMECs or stably expressing WT-SHP-2 or Dn-SHP-2 as described in Material and methods. Immunoprecipitated proteins were eluted with SDS-sample buffer, and resolved on 7.5% SDS-PAGE followed by immunoblotting with anti-phosphotyrosine antibody (4 G10) or anti-cortactin antibody. Lanes a, d, g: basal condition; lanes b, e, h: ICAM-1 cross-linking; lanes c, f, i: sequential ICAM-1 and PECAM-1 cross-linking.
###end p 43
###begin p 44
###xml 236 243 236 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Fig. 3a</xref>
###xml 845 852 845 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Fig. 3b</xref>
###xml 1024 1031 1024 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Fig. 3b</xref>
###xml 1297 1304 1297 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Fig. 4a</xref>
###xml 1449 1455 1449 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1435 1460 1435 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">Schoenwaelder <italic>et al.</italic> 2000</xref>
###xml 1477 1483 1477 1483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1462 1488 1462 1488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Gopalakrishnan <italic>et al.</italic> 2003</xref>
###xml 1611 1618 1611 1618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Fig. 4e</xref>
Moreover, focusing on ICAM-1 signaling pathway, we observed a slight but consistent increase in the amount of SHP-2 in ICAM-1 immunoprecipitates following antibody cross-linking, although we failed to detect any ICAM-1 phosphorylation (Fig. 3a, lane d): this result suggested a non-conventional or indirect interaction between ICAM-1 and SHP-2. Similar results were observed using HBMECs (not shown). To further assess a functional role for SHP-2 in ICAM-1-coupled signaling pathways, we established endothelial cell lines stably expressing a dominant negative form of SHP-2 (Dn-SHP-2) or the wild type enzyme (WT-SHP-2) as a control; for technical reasons, HBMECs were used in this approach. Following antibody cross-linking of ICAM-1, we observed that expression of Dn-SHP-2 abolished the ICAM-1 induced tyrosine phosphorylation of cortactin (Fig. 3b, lane h), pointing to SHP-2 as a positive regulator of the Src-cortactin pathway in endothelial cells. By contrast, over-expression of the wild type enzyme had no effect (Fig. 3b, lane e), suggesting that endogenous SHP-2 activity was sufficient for a maximal stimulation of cortactin phosphorylation by ICAM-1 cross-linking. Immunoblotting with anti SHP-2 antibody (not shown) was used for control of sample loading. Interestingly, calpeptin (Fig. 4a, lane e), a known calpain inhibitor which was previously identified and characterized as a selective inhibitor of SHP-2 activity (Schoenwaelder et al. 2000; Gopalakrishnan et al. 2003) drastically affected the formation of actin stress fibers in response to antibody cross-linking of ICAM-1 in RBE4 cells (Fig. 4e) and in HBMECs (not shown).
###end p 44
###begin p 45
The SHP-2 inhibitor calpeptin mimicks PECAM-1-induced reversal of ICAM-1 signaling. Panel (a) Sequential cross-linking of ICAM-1 and/or PECAM-1 was performed on IFN-gamma-treated RBE4 cells pre-incubated with or without the selective SHP-2 inhibitor calpeptin (150 mug/mL) as described in Material and methods. Following cortactin immunoprecipitation, immunoblotting with anti-phosphotyrosine antibodies (clone 4 G10) or anti-cortactin antibodies detected tyrosine-phosphorylated cortactin or total amount of cortactin, respectively. Lanes a, d: basal condition; lanes b, e: ICAM-1 cross-linking; lanes c, f: sequential ICAM-1 and PECAM-1 cross-linking. Panels (b-e) IFN-gamma-treated RBE4 cells were treated or not with calpeptin (150 mug/mL for 30 min) prior to ICAM-1 cross-linking. Cells were fixed and actin was stained by using 0.1 mug/mL of tetramethylrhodamine isothiocyanate-labeled phalloidin. Panel (b) Basal condition. Panel (c) ICAM-1 cross-linking. Panel (d) Basal condition after calpeptin treatment. Panel (e) ICAM-1 cross-linking after calpeptin treatment.
###end p 45
###begin p 46
###xml 72 78 72 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">Fig. 5</xref>
In conclusion, the main findings of the current study are summarized in Fig. 5: they demonstrate that SHP-2 is positively involved in ICAM-1 signaling, upstream of the tyrosine phosphorylation of cortactin by Src and of RhoA-mediated actin cytoskeleton rearrangements. More importantly, our results show that PECAM-1 engagement, which induces a strong interaction with SHP-2, drastically inhibits these two distinct ICAM-1 activated pathways. Together, these results suggest that SHP-2 might be a key player at the crossroads between ICAM-1 and PECAM-1 signalings in endothelial cells.
###end p 46
###begin p 47
Cross-talk between ICAM-1 and PECAM-1-coupled signaling pathways. SHP-2 is positively involved in ICAM-1 signaling, upstream of the tyrosine phosphorylation of cortactin by Src and of RhoA-mediated actin cytoskeleton rearrangements. In this study, we show that PECAM-1 engagement, which induces a strong interaction with SHP-2, drastically inhibits these two distinct ICAM-1 activated pathways. Together, we propose that SHP-2 might be a key player at the crossroads between ICAM-1 and PECAM-1 signalings in endothelial cells.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 227 230 <span type="species:ncbi:10116">rat</span>
We show in the present study that PECAM-1 engagement by antibody cross-linking totally blocked ICAM-1-induced activation of RhoA and subsequent changes in actin cytoskeleton, as well as tyrosine phosphorylation of cortactin in rat brain endothelial cells. Moreover, these findings suggest that the tyrosine phosphatase SHP-2, as an upstream mediator of both PECAM-1 and ICAM-1 signaling pathways, might be a key player in the cross-talk identified here between these pathways.
###end p 49
###begin p 50
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 135 155 135 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">Barreiro <italic>et al.</italic> 2002</xref>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 157 175 157 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Carman <italic>et al.</italic> 2003</xref>
###xml 742 748 742 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 734 753 734 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">Etienne <italic>et al.</italic> 1998</xref>
###xml 763 769 763 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 755 774 755 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Adamson <italic>et al.</italic> 1999</xref>
###xml 795 801 795 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 776 806 776 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Etienne-Manneville <italic>et al.</italic> 2000</xref>
###xml 1282 1288 1275 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1273 1293 1266 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">Federici <italic>et al.</italic> 1996</xref>
###xml 1301 1307 1294 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1295 1312 1288 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">Celli <italic>et al.</italic> 2006</xref>
###xml 1452 1461 1445 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide</italic>
###xml 1559 1565 1552 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1550 1570 1543 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">Pluskota <italic>et al.</italic> 2000</xref>
###xml 1577 1583 1570 1576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1572 1588 1565 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">Wang <italic>et al.</italic> 2003</xref>
###xml 1855 1861 1848 1854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1845 1866 1838 1859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">Greenwood <italic>et al.</italic> 2003</xref>
###xml 482 485 <span type="species:ncbi:10116">rat</span>
###xml 894 897 <span type="species:ncbi:10116">rat</span>
###xml 920 925 <span type="species:ncbi:9606">human</span>
Accumulating evidence indicates that, beyond its ability to contribute to the formation of "docking" sites for circulating leucocytes (Barreiro et al. 2002; Carman et al. 2003), ICAM-1 behaves as a signal transducer, activating multiple signaling pathways in endothelial cells. ICAM-1 signaling in endothelial cells thus appears to participate in the trans-endothelial migration of leucocytes to inflammation sites. We previously identified multiple signaling pathways activated in rat brain endothelial cell lines, following ICAM-1 cross-linking or leukocyte adhesion. In particular, we demonstrated activation of the tyrosine kinase Src and tyrosine phosphorylation of several cytoskeleton-associated proteins, including cortactin (Etienne et al. 1998; Adamson et al. 1999; Etienne-Manneville et al. 2000). In spite of the short C-terminal domain of ICAM-1, which comprises 27 amino acids in rat and 28 amino acids in human, biochemical studies have demonstrated that ICAM-1 is capable of binding a number of intracellular proteins in endothelial cells: the actin-binding protein alpha-actinin, the microtubule-associated beta-tubulin, the enzyme glyceraldehyde-3-phosphate dehydrogenase and ezrin, a linker between integral membrane proteins and the actin-cytoskeleton (Federici et al. 1996; Celli et al. 2006). In addition, it has been suggested that SHP-2 might associate with tyrosine phosphorylated ICAM-1, even though ICAM-1 does not contain a bona fide SHP-2 binding site, such as a consensus immunoreceptor tyrosine-based inhibitory motif (Pluskota et al. 2000; Wang et al. 2003). In the present study, the moderate amount of SHP-2 bound to ICAM-1 (compared with SHP-2 bound to PECAM-1) following antibody cross-linking may be related to a very low level of ICAM-1 tyrosine phosphorylation (not detected here or in a previous studies (Greenwood et al. 2003)) or may reflect interaction with a putative non-conventional motif in the ICAM-1 cytoplasmic domain. Alternatively, interaction between ICAM-1 and SHP-2 might be indirect, via an unidentified protein linker.
###end p 50
###begin p 51
###xml 209 215 209 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 200 220 200 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">Pluskota <italic>et al.</italic> 2000</xref>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 222 241 222 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">Lacalle <italic>et al.</italic> 2002</xref>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 243 259 243 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">Wang <italic>et al.</italic> 2003</xref>
###xml 272 278 272 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 261 283 261 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">Kontaridis <italic>et al.</italic> 2004</xref>
###xml 542 548 542 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig05">Fig. 5</xref>
SHP-2 is known as an upstream mediator of multiple signaling pathways, but contrasting data in various cell systems present it either as a negative or a positive regulator of RhoA and other pathways (Pluskota et al. 2000; Lacalle et al. 2002; Wang et al. 2003; Kontaridis et al. 2004). Here we showed that a dominant negative form of SHP-2 (Dn-SHP-2) or calpeptin inhibition of SHP-2 enzymatic activity largely inhibited the ICAM-1-mediated tyrosine phosphorylation of cortactin and actin stress fiber formation. These results, summarized in Fig. 5, clearly establish that SHP-2 is positively involved in ICAM-1 signaling in endothelial cells, upstream of the Src-mediated tyrosine phosphorylation of cortactin as well as RhoA-mediated actin cytoskeleton rearrangements.
###end p 51
###begin p 52
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 250 268 250 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">Masuda <italic>et al.</italic> 1997</xref>
###xml 279 285 279 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 270 290 270 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">Henshall <italic>et al.</italic> 2001</xref>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 292 309 292 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">Patil <italic>et al.</italic> 2001</xref>
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 311 329 311 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">Cicmil <italic>et al.</italic> 2002</xref>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 331 353 331 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Gratzinger <italic>et al.</italic> 2003</xref>
###xml 355 367 355 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">Jackson 2003</xref>
###xml 369 391 369 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">Newman and Newman 2003</xref>
###xml 1476 1482 1476 1482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1469 1487 1469 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">Newman <italic>et al.</italic> 2001</xref>
###xml 1489 1511 1489 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">Newman and Newman 2003</xref>
###xml 1805 1824 1794 1813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">Ilan and Madri 2003</xref>
PECAM-1 has been convincingly shown to transduce inhibitory signals in a variety of cell types, including endothelial cells, through SHP-2 binding to a tyrosine-phosphorylated immunoreceptor tyrosine-based inhibitory motif in its cytoplasmic domain (Masuda et al. 1997; Henshall et al. 2001; Patil et al. 2001; Cicmil et al. 2002; Gratzinger et al. 2003; Jackson 2003; Newman and Newman 2003). The results of the present study showed that PECAM-1 engagement concomitantly induced SHP-2 binding to PECAM-1 and blocked the SHP-2-dependent phosphorylation of cortactin and rearrangements of the actin cytoskeleton evoked by ICAM-1. This is to our knowledge the first evidence that PECAM-1 engagement can negatively regulate the signaling pathways coupled to another leukocyte adhesion molecule in endothelial cells. This observation strongly suggests that leukocyte adhesion and transmigration trigger in endothelial cells a complex set of interconnected positive and negative signalings which cooperate for controlling the dynamics of endothelial response. Although our study cannot firmly establish a direct role for SHP-2 in PECAM-1-coupled inhibition of ICAM-1 signaling, it is tempting to speculate that activated PECAM-1, by efficiently recruiting SHP-2, may sequester it away from ICAM-1 and inhibit RhoA and Src activation. This hypothesis is in line with the interpretation proposed for PECAM-1 inhibition of growth factor or antigen receptor signaling pathways (Newman et al. 2001; Newman and Newman 2003). Alternatively, other proteins involved in the maintenance of endothelial junction integrity such as beta- or gamma-catenin, PLC-gamma, which are also known to interact with the cytosolic domain of PECAM-1, might be involved in the regulatory loop identified here between ICAM-1 and PECAM-1 (Ilan and Madri 2003). However, we did not observe in the present study any detectable association between PECAM-1 and beta- or gamma-catenin (not shown).
###end p 52
###begin p 53
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 211 239 211 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Durieu-Trautmann <italic>et al.</italic> 1994</xref>
###xml 251 257 251 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 241 262 241 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Greenwood <italic>et al.</italic> 2002</xref>
###xml 264 288 264 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Carman and Springer 2004</xref>
###xml 295 301 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 290 306 290 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">Shaw <italic>et al.</italic> 2004</xref>
###xml 313 319 313 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 308 324 308 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">Yang <italic>et al.</italic> 2005</xref>
###xml 333 339 333 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 326 344 326 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">Millan <italic>et al.</italic> 2006</xref>
###xml 547 553 547 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 539 558 539 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Adamson <italic>et al.</italic> 1999</xref>
###xml 579 585 579 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 560 590 560 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Etienne-Manneville <italic>et al.</italic> 2000</xref>
###xml 830 836 830 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 822 841 822 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">Walters <italic>et al.</italic> 2002</xref>
###xml 994 1000 994 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 989 1005 989 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">Yang <italic>et al.</italic> 2005</xref>
###xml 1007 1011 1007 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">2006</xref>
We and others provided compelling evidence that ICAM-1-induced signaling and subsequent actin cytoskeleton remodeling was directly involved in the process of trans-endothelial migration of activated leukocytes (Durieu-Trautmann et al. 1994; Greenwood et al. 2002; Carman and Springer 2004; Shaw et al. 2004; Yang et al. 2005; Millan et al. 2006). Pharmacological inhibition of ICAM-1 coupled signalling pathways, using Rho kinase inhibitors or calcium chelators, largely prevented the migration of activated lymphocytes across RBE4 cells (Adamson et al. 1999; Etienne-Manneville et al. 2000). Moreover, we demonstrated that inhibition of Rho GTPases with protein prenyltransferase inhibitors prevented leukocyte recruitment to the CNS and attenuated clinical signs of disease in Experimental Autoimmune Encephalomyelitis (Walters et al. 2002). Complementary experiments demonstrated that the ICAM-1-induced Src-cortactin pathway is essential for trans-endothelial migration of leukocytes (Yang et al. 2005, 2006).
###end p 53
###begin p 54
###xml 185 209 185 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Carman and Springer 2004</xref>
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 211 227 211 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">Shaw <italic>et al.</italic> 2004</xref>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 229 249 229 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">Barreiro <italic>et al.</italic> 2005</xref>
###xml 258 264 258 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 251 269 251 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Doulet <italic>et al.</italic> 2006</xref>
###xml 1715 1721 1715 1721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1708 1726 1708 1726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">Millan <italic>et al.</italic> 2006</xref>
###xml 1735 1741 1735 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1728 1746 1728 1746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">Viegas <italic>et al.</italic> 2006</xref>
Moreover, recent studies have demonstrated that leukocyte adhesion promotes the remodeling of the apical endothelial plasma membrane into projections that surround adherent leukocytes (Carman and Springer 2004; Shaw et al. 2004; Barreiro et al. 2005; Doulet et al. 2006). These structures, referred to as endothelial docking structures or transmigratory cups, are essential to promote firm adhesion and extravasation of leukocytes through paracellular as well as transcellular routes. Formation of these docking structures results from the dynamic redistribution of several adhesion molecules including ICAM-1 and actin polymerization. The current study strongly suggests that PECAM-1 engagement during paracellular extravasation of leukocytes, which has been well-documented to contribute to leukocyte diapedesis, may also regulate this process by limiting the ICAM-1 induced actin cytoskeleton rearrangements, downstream of the formation of docking structures. Future studies will aim at evaluating the functional relevance of these findings, by evaluating the role of the PECAM-1 cytoplasmic domain and associated signaling in regulation of leukocyte transmigration across brain endothelial cells. In addition, because PECAM-1 is not present in endothelial docking structures, it will be necessary to identify the cellular compartments where the signalling cross-talk reported here may take place. It can be hypothesized that caveolae or caveolin-rich microdomains may facilitate the functional interaction between ICAM-1- and PECAM-1 signalings in as much as PECAM-1 is present in these structures whereas ICAM-1 was recently shown to be recruited in similar structures following antibody cross-linking (Millan et al. 2006; Viegas et al. 2006). Further experiments will be required to substantiate this hypothesis.
###end p 54
###begin p 55
We sincerely thank Dr Sylvie Cazaubon and Dr Clara Nahmias for helpful discussions and critical reading of the manuscript and the Wellcome Trust for a programme grant to JG. This work was supported by grants from the Association pour la Recherche sur la Sclerose en Plaques (ARSEP), the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Sante et de la Recherche Medicale (INSERM) and Sidaction.
###end p 55
###begin title 56
References
###end title 56
###begin article-title 57
Lymphocyte migration through brain endothelial cell monolayers involves signaling through endothelial ICAM-1 via a rho-dependent pathway
###end article-title 57
###begin article-title 58
Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes
###end article-title 58
###begin article-title 59
Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation
###end article-title 59
###begin article-title 60
Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity
###end article-title 60
###begin article-title 61
A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them
###end article-title 61
###begin article-title 62
Endothelial cells proactively form microvilli-like membrane projections upon intercellular adhesion molecule 1 engagement of leukocyte LFA-1
###end article-title 62
###begin article-title 63
CNS immune privilege: hiding in plain sight
###end article-title 63
###begin article-title 64
Evidence of a functional role for interaction between ICAM-1 and nonmuscle alpha-actinins in leukocyte diapedesis
###end article-title 64
###begin article-title 65
###xml 83 88 <span type="species:ncbi:9606">human</span>
Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets
###end article-title 65
###begin article-title 66
###xml 0 22 <span type="species:ncbi:487">Neisseria meningitidis</span>
###xml 36 41 <span type="species:ncbi:9606">human</span>
Neisseria meningitidis infection of human endothelial cells interferes with leukocyte transmigration by preventing the formation of endothelial docking structures
###end article-title 66
###begin article-title 67
Intercellular adhesion molecule 1 activation induces tyrosine phosphorylation of the cytoskeleton-associated protein cortactin in brain microvessel endothelial cells
###end article-title 67
###begin article-title 68
Molecular mechanisms involved in T cell migration across the blood-brain barrier
###end article-title 68
###begin article-title 69
ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells
###end article-title 69
###begin article-title 70
MHC class II engagement in brain endothelial cells induces protein kinase A-dependent IL-6 secretion and phosphorylation of cAMP response element-binding protein
###end article-title 70
###begin article-title 71
ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines
###end article-title 71
###begin article-title 72
Association of the cytoplasmic domain of intercellular-adhesion molecule-1 with glyceraldehyde-3-phosphate dehydrogenase and beta-tubulin
###end article-title 72
###begin article-title 73
Differential regulation of junctional complex assembly in renal epithelial cell lines
###end article-title 73
###begin article-title 74
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice
###end article-title 74
###begin article-title 75
Platelet-endothelial cell adhesion molecule-1 modulates endothelial migration through its immunoreceptor tyrosine-based inhibitory motif
###end article-title 75
###begin article-title 76
Lymphocyte migration into the central nervous system: implication of ICAM-1 signalling at the blood-brain barrier
###end article-title 76
###begin article-title 77
Intracellular domain of brain endothelial intercellular adhesion molecule-1 is essential for T lymphocyte-mediated signaling and migration
###end article-title 77
###begin article-title 78
Src homology 2 domain-containing protein-tyrosine phosphatases, SHP-1 and SHP-2, are required for platelet endothelial cell adhesion molecule-1/CD31-mediated inhibitory signaling
###end article-title 78
###begin article-title 79
###xml 87 109 <span type="species:ncbi:487">Neisseria meningitidis</span>
Activation of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by Neisseria meningitidis
###end article-title 79
###begin article-title 80
PECAM-1: old friend, new partners
###end article-title 80
###begin article-title 81
The unfolding tale of PECAM-1
###end article-title 81
###begin article-title 82
SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway
###end article-title 82
###begin article-title 83
Specific SHP-2 partitioning in raft domains triggers integrin-mediated signaling via Rho activation
###end article-title 83
###begin article-title 84
Platelet endothelial cell adhesion molecule-1 is a major SH-PTP2 binding protein in vascular endothelial cells
###end article-title 84
###begin article-title 85
Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains
###end article-title 85
###begin article-title 86
PECAM-1 is required for transendothelial migration of leukocytes
###end article-title 86
###begin article-title 87
Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology
###end article-title 87
###begin article-title 88
Inhibition of antigen-receptor signaling by Platelet Endothelial Cell Adhesion Molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56(lck)
###end article-title 88
###begin article-title 89
Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen
###end article-title 89
###begin article-title 90
Src homology domain 2-containing tyrosine phosphatase 2 associates with intercellular adhesion molecule 1 to regulate cell survival
###end article-title 90
###begin article-title 91
Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain
###end article-title 91
###begin article-title 92
The phosphotyrosine phosphatase PTP1D, but not PTP1C, is an essential mediator of fibroblast proliferation induced by tyrosine kinase and G protein-coupled receptors
###end article-title 92
###begin article-title 93
###xml 96 99 <span type="species:ncbi:10116">rat</span>
Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells
###end article-title 93
###begin article-title 94
Rho-like GTPases: their role in epithelial cell-cell adhesion and invasion
###end article-title 94
###begin article-title 95
Locomotion of monocytes on endothelium is a critical step during extravasation
###end article-title 95
###begin article-title 96
The protein tyrosine phosphatase Shp-2 regulates RhoA activity
###end article-title 96
###begin article-title 97
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 154 159 <span type="species:ncbi:9606">human</span>
Characterization of a newly established human bone marrow endothelial cell line: distinct adhesive properties for hematopoietic progenitors compared with human umbilical vein endothelial cells
###end article-title 97
###begin article-title 98
Coordinated redistribution of leukocyte LFA-1 and endothelial cell ICAM-1 accompany neutrophil transmigration
###end article-title 98
###begin article-title 99
###xml 117 122 <span type="species:ncbi:9606">human</span>
Junctional expression of the prion protein PrPC by brain endothelial cells: a role in trans-endothelial migration of human monocytes
###end article-title 99
###begin article-title 100
Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis
###end article-title 100
###begin article-title 101
Activation of Src tyrosine kinases in response to ICAM-1 ligation in pulmonary microvascular endothelial cells
###end article-title 101
###begin article-title 102
ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow
###end article-title 102
###begin article-title 103
Endothelial cell cortactin coordinates intercellular adhesion molecule-1 clustering and actin cytoskeleton remodeling during polymorphonuclear leukocyte adhesion and transmigration
###end article-title 103
###begin title 104
Abbreviations used
###end title 104
###begin p 105
###xml 0 5 <span type="species:ncbi:9606">human</span>
human bone marrow endothelial cell line
###end p 105
###begin p 106
intercellular adhesion molecule-1
###end p 106
###begin p 107
major histocompatibility complex
###end p 107
###begin p 108
platelet/endothelial cell-adhesion molecule-1
###end p 108
###begin p 109
###xml 0 3 <span type="species:ncbi:10116">rat</span>
rat brain endothelial cell line 4
###end p 109

